Ivan M Robbins1, John H Newman2, Roger F Johnson2, Anna R Hemnes2, Richard D Fremont2, Robert N Piana3, David X Zhao3, Daniel W Byrne4. 1. Pulmonary Vascular Center, Vanderbilt University School of Medicine, Nashville, TN. Electronic address: ivan.robbins@vanderbilt.edu. 2. Pulmonary Vascular Center, Vanderbilt University School of Medicine, Nashville, TN. 3. Division of Allergy, Pulmonary and Critical Care Medicine, the Division of Cardiology, Vanderbilt University School of Medicine, Nashville, TN. 4. Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN.
Abstract
BACKGROUND: Pulmonary venous hypertension (PVH) is a well-described cause of pulmonary hypertension (PH) in patients with left heart disease associated with elevated left heart filling pressure. PVH results from a number of processes, including left-sided valvular disease, constrictive pericardial disease, restrictive cardiomyopathies, and left ventricular (LV) systolic dysfunction. PVH in patients with normal LV systolic function, commonly referred to as diastolic dysfunction, is not well characterized. We observed that many patients with PH due to PVH have obesity, hypertension, diabetes mellitus, and hypercholesterolemia, which are clinical features of the metabolic syndrome (MS), a previously identified cause for systemic vascular disease. METHODS: We evaluated 122 consecutive patients referred for diagnosis and treatment of PH and compared the prevalence of features of the MS between patients with PVH and those with pulmonary arterial hypertension (PAH). We also compared clinical and hemodynamic characteristics between these two groups. RESULTS: Compared to patients with PAH, patients with PVH had a higher frequency of hypertension, obesity, diabetes mellitus, and hyperlipidemia. Two or more features of the MS were found in 16 of 17 patients with PVH (94.1%) compared with 34.3% of patients with PAH (p < 0.001; odds ratio, 30.7; 95% confidence interval, 3.6 to 260.0). PH was substantial, but less severe overall, in patients with PVH compared to those with PAH (mean pulmonary artery pressure, 45 +/- 17 mm Hg [range, 26 to 71 mm Hg] vs 53 +/- 10 [range, 33 to 72 mm Hg], respectively [p = 0.041]; and pulmonary vascular resistance, 4.4 +/- 2.9 units [range, 1.2 to 10.8 units] vs 10.8 +/- 4.7 units [range, 4.8 to 21.9 units], respectively [p < 0.001]). CONCLUSION: PVH is highly associated with the MS. Our results suggest that the MS may predispose patients to develop pulmonary vascular disease.
BACKGROUND:Pulmonary venous hypertension (PVH) is a well-described cause of pulmonary hypertension (PH) in patients with left heart disease associated with elevated left heart filling pressure. PVH results from a number of processes, including left-sided valvular disease, constrictive pericardial disease, restrictive cardiomyopathies, and left ventricular (LV) systolic dysfunction. PVH in patients with normal LV systolic function, commonly referred to as diastolic dysfunction, is not well characterized. We observed that many patients with PH due to PVH have obesity, hypertension, diabetes mellitus, and hypercholesterolemia, which are clinical features of the metabolic syndrome (MS), a previously identified cause for systemic vascular disease. METHODS: We evaluated 122 consecutive patients referred for diagnosis and treatment of PH and compared the prevalence of features of the MS between patients with PVH and those with pulmonary arterial hypertension (PAH). We also compared clinical and hemodynamic characteristics between these two groups. RESULTS: Compared to patients with PAH, patients with PVH had a higher frequency of hypertension, obesity, diabetes mellitus, and hyperlipidemia. Two or more features of the MS were found in 16 of 17 patients with PVH (94.1%) compared with 34.3% of patients with PAH (p < 0.001; odds ratio, 30.7; 95% confidence interval, 3.6 to 260.0). PH was substantial, but less severe overall, in patients with PVH compared to those with PAH (mean pulmonary artery pressure, 45 +/- 17 mm Hg [range, 26 to 71 mm Hg] vs 53 +/- 10 [range, 33 to 72 mm Hg], respectively [p = 0.041]; and pulmonary vascular resistance, 4.4 +/- 2.9 units [range, 1.2 to 10.8 units] vs 10.8 +/- 4.7 units [range, 4.8 to 21.9 units], respectively [p < 0.001]). CONCLUSION: PVH is highly associated with the MS. Our results suggest that the MS may predispose patients to develop pulmonary vascular disease.
Authors: Gerald Simonneau; Nazzareno Galiè; Lewis J Rubin; David Langleben; Werner Seeger; Guido Domenighetti; Simon Gibbs; Didier Lebrec; Rudolf Speich; Maurice Beghetti; Stuart Rich; Alfred Fishman Journal: J Am Coll Cardiol Date: 2004-06-16 Impact factor: 24.094
Authors: Marc Klapholz; Matthew Maurer; April M Lowe; Frank Messineo; Jay S Meisner; Judith Mitchell; Jill Kalman; Robert A Phillips; Richard Steingart; Edward J Brown; Robert Berkowitz; Robert Moskowitz; Anita Soni; Donna Mancini; Rachel Bijou; Khashayar Sehhat; Nikita Varshneya; Marrick Kukin; Stuart D Katz; Lynn A Sleeper; Thierry H Le Jemtel Journal: J Am Coll Cardiol Date: 2004-04-21 Impact factor: 24.094
Authors: Stefan C Bertog; Senthil K Thambidorai; Kapil Parakh; Paul Schoenhagen; Volkan Ozduran; Penny L Houghtaling; Bruce W Lytle; Eugene H Blackstone; Michael S Lauer; Allan L Klein Journal: J Am Coll Cardiol Date: 2004-04-21 Impact factor: 24.094
Authors: Margaret M Redfield; Steven J Jacobsen; John C Burnett; Douglas W Mahoney; Kent R Bailey; Richard J Rodeheffer Journal: JAMA Date: 2003-01-08 Impact factor: 56.272
Authors: Yoram Neuman; Andy Kotliroff; Tamir Bental; Robert J Siegel; Daniel David; Michael Lishner Journal: Int J Cardiol Date: 2007-07-23 Impact factor: 4.164
Authors: Anna R Hemnes; Aaron W Trammell; Stephen L Archer; Stuart Rich; Chang Yu; Hui Nian; Niki Penner; Mitchell Funke; Lisa Wheeler; Ivan M Robbins; Eric D Austin; John H Newman; James West Journal: Circulation Date: 2014-10-31 Impact factor: 29.690
Authors: Serpil Erzurum; Sharon I Rounds; Troy Stevens; Micheala Aldred; Jason Aliotta; Stephen L Archer; Kewal Asosingh; Robert Balaban; Natalie Bauer; Jahar Bhattacharya; Harm Bogaard; Gaurav Choudhary; Gerald W Dorn; Raed Dweik; Karen Fagan; Michael Fallon; Toren Finkel; Mark Geraci; Mark T Gladwin; Paul M Hassoun; Marc Humbert; Naftali Kaminski; Steven M Kawut; Joseph Loscalzo; Donald McDonald; Ivan F McMurtry; John Newman; Mark Nicolls; Marlene Rabinovitch; Judy Shizuru; Masahiko Oka; Peter Polgar; David Rodman; Paul Schumacker; Kurt Stenmark; Rubin Tuder; Norbert Voelkel; Eugene Sullivan; Richard Weinshilboum; Mervin C Yoder; Yingming Zhao; Dorothy Gail; Timothy M Moore Journal: Am J Respir Crit Care Med Date: 2010-09-10 Impact factor: 21.405
Authors: Cynthia W Baffi; Lisa Wood; Daniel Winnica; Patrick J Strollo; Mark T Gladwin; Loretta G Que; Fernando Holguin Journal: Chest Date: 2016-01-20 Impact factor: 9.410
Authors: Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes Journal: J Heart Lung Transplant Date: 2011-04-13 Impact factor: 10.247
Authors: Carl D Koch; Mark T Gladwin; Bruce A Freeman; Jon O Lundberg; Eddie Weitzberg; Alison Morris Journal: Free Radic Biol Med Date: 2016-12-16 Impact factor: 7.376
Authors: Ivan M Robbins; Anna R Hemnes; Meredith E Pugh; Evan L Brittain; David X Zhao; Robert N Piana; Pete P Fong; John H Newman Journal: Circ Heart Fail Date: 2013-12-02 Impact factor: 8.790